MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain, remaining incurable with a median survival time of only 15 months. In an effort to identify new targets for GBM diagnostics and therapeutics, recent studies have focused on molecular phenotyping of GBM subtypes. This has resulted in mounting interest in microRNAs (miRNAs) due to their regulatory capacities in both normal development and in pathological conditions such as cancer. miRNAs have a wide range of targets, allowing them to modulate many pathways critical to cancer progression, including proliferation, cell death, metastasis, angiogenesis, and drug resistance. This review explores our current understanding of miRNAs that are differentially modulated and pathologically involved in GBM as well as the current state of miRNA-based therapeutics. As the role of miRNAs in GBM becomes more well understood and novel delivery methods are developed and optimized, miRNA-based therapies could provide a critical step forward in cancer treatment.
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Amanda
A
Shea
Groton School, Groton, Massachusetts, 01450.
Varsha
V
Harish
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Zainab
Z
Afzal
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Juliet
J
Chijioke
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Habib
H
Kedir
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Shahnoza
S
Dusmatova
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Arpita
A
Roy
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
Malathi
M
Ramalinga
Department of Neurology and Pathology, Georgetown University, Washington, District of Columbia, 20057.
Brent
B
Harris
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, 20057.
Jan
J
Blancato
Division of Cancer Control and Population Sciences, National Cancer Institute (NCI), National Institutes of Health (NIH), Rockville, Maryland, 20850.
Mukesh
M
Verma
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.|Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, 20057.
Deepak
D
Kumar
D000818:Animals; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy / Q000379:methods; D005909:Glioblastoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D034622:RNA Interference
D035683:MicroRNAs
cancer therapy; glioblastoma multiforme; microRNA